Harmony Biosciences (HRMY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report) has received an average rating of “Buy” from the seven research firms that are currently covering the stock, MarketBeat.com reports. Five ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is pleased to announce that its pioneering CAR-T ...

Avidity Biosciences specializes in RNA-based therapies using Antibody-oligonucleotide conjugates to deliver drugs directly to ...

Scale Biosciences (Scale Biotm), a leader in innovative and scalable single cell analysis solutions, today announced the availability of its QuantumScale Single Cell RNA kits, a set of next-generation ...

Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of cancer therapies called RIPTACtm (Regulated Induced Proximity TArgeting Chimeras) therapeutics, today announced ...

MSS Hosts Korea-Japan Startup Investment Summit 2025 SEJONG – On February 21, the Ministry of SMEs and Startups of the Republic of Korea (MSS ...

The rising global cancer incidence is a key factor driving the CD47 inhibitors market, as the demand for novel therapies grows. Recent clinical trial ...

The larvicides market is growing due to rising vector-borne diseases, increased mosquito control efforts, and eco-friendly solutions in public health and agriculture. ” - Exactitude Consultancy ...

The U.S. stock market took a hit on Friday as a wave of troubling economic news sent all major indexes tumbling. The S&P 500 suffered its worst drop in two months, sinking 1.7%, while the Dow and ...

The New College Institute (NCI) in Martinsville has received a solid endorsement from the General Assembly as they wrapped up ...